These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 1516252)

  • 21. Humoral response to recombinant interferon-alpha 2b in patients receiving recombinant interferon-alpha 2b therapy.
    von Wussow P; Jakschies D; Freund M; Deicher H
    J Interferon Res; 1989 Sep; 9 Suppl 1():S25-31. PubMed ID: 2809276
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum-induced suppression of interferon (IFN) activity. Lack of evidence for the presence of specific autoantibodies to IFN-alpha in normal human sera.
    Hansen MB; Svenson M; Bendtzen K
    Clin Exp Immunol; 1992 Jun; 88(3):559-62. PubMed ID: 1606741
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibodies developing against a single recombinant interferon protein may neutralize many other interferon-alpha subtypes.
    Brand CM; Leadbeater L; Bellati G; Marotta F; Ideo G
    J Interferon Res; 1993 Apr; 13(2):121-5. PubMed ID: 7685368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized, placebo-controlled trial of nonpegylated and pegylated forms of recombinant human alpha interferon 2a for suppression of dengue virus viremia in rhesus monkeys.
    Ajariyakhajorn C; Mammen MP; Endy TP; Gettayacamin M; Nisalak A; Nimmannitya S; Libraty DH
    Antimicrob Agents Chemother; 2005 Nov; 49(11):4508-14. PubMed ID: 16251289
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natural leukocyte interferon-alpha therapy in patients with chronic granulocytic leukemia who have antibody-mediated resistance to treatment with recombinant interferon-alpha.
    Tefferi A; Grendahl DC
    Am J Hematol; 1996 Jul; 52(3):231-3. PubMed ID: 8756097
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does the presence of serum autoantibodies influence the responsiveness to interferon-alpha 2a treatment in chronic hepatitis C?
    Wada M; Kang KB; Kinugasa A; Shintani S; Sawada K; Nishigami T; Shimoyama T
    Intern Med; 1997 Apr; 36(4):248-54. PubMed ID: 9187562
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prolonged, continuous treatment of hairy cell leukemia patients with recombinant interferon-alpha 2a.
    Smith JW; Longo DL; Urba WJ; Clark JW; Watson T; Beveridge J; Conlon KC; Sznol M; Creekmore SP; Alvord WG
    Blood; 1991 Oct; 78(7):1664-71. PubMed ID: 1912555
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-interferon alpha antibodies and autoantibodies in patients with Behçet's disease uveitis treated with recombinant human interferon alpha-2a.
    Aydinoglu-Candan Ö; Araz-Erşan B; Gul A; Badur S; Tugal-Tutkun I
    Graefes Arch Clin Exp Ophthalmol; 2015 Mar; 253(3):457-65. PubMed ID: 25500983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interferon (IFN)-alpha 2 genotype analysis of Chinese chronic hepatitis B patients undergoing recombinant IFN-alpha 2a therapy.
    Crowe JS; Gewert DR; Barber KA; Lewis AP; Sims MJ; Davies SL; Salom CL; Wood J; Thomas HC; Thursz M
    J Infect Dis; 1994 Apr; 169(4):875-8. PubMed ID: 8133104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Naturally occurring anti-interferon-alpha 2a antibodies in patients with acute viral hepatitis.
    Ikeda Y; Toda G; Hashimoto N; Umeda N; Miyake K; Yamanaka M; Kurokowa K
    Clin Exp Immunol; 1991 Jul; 85(1):80-4. PubMed ID: 1906385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The incidence and clinical significance of antibodies to interferon-a in patients with solid tumors.
    Oberg K; Alm G
    Biotherapy; 1997; 10(1):1-5. PubMed ID: 9261544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The interferon-alpha 2b gene in Japanese patients with chronic viral hepatitis who developed antibodies after treatment with recombinant interferon-alpha 2a.
    Hosoi H; Imai M; Yamanaka M
    J Gastroenterol Hepatol; 1992; 7(4):411-6. PubMed ID: 1515568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selective decrease in Leu8-negative T cell subpopulations following treatment with recombinant interferon-alpha 2a (rIFN-alpha 2a).
    Martínez-Maza O; Figlin RA; Giorgi JV; Fahey JL
    Cell Immunol; 1988 Nov; 117(1):89-98. PubMed ID: 2902935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma.
    Bajetta E; Di Leo A; Zampino MG; Sertoli MR; Comella G; Barduagni M; Giannotti B; Queirolo P; Tribbia G; Bernengo MG
    J Clin Oncol; 1994 Apr; 12(4):806-11. PubMed ID: 8151323
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low incidence of anti-interferon-alpha antibodies in patients treated with interferon-alpha-2a for AIDS-associated Kaposi's sarcoma.
    de Wit R; Bakker PJ; Danner SA; Goudsmit J; Veenhof KH
    Int J STD AIDS; 1990 Jul; 1(4):256-8. PubMed ID: 2088534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence of response and long-term follow-up in patients with hairy cell leukemia treated with recombinant interferon alfa-2a.
    Berman E; Heller G; Kempin S; Gee T; Tran LL; Clarkson B
    Blood; 1990 Feb; 75(4):839-45. PubMed ID: 2302457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence and in-vivo relevance of anti-interferon antibodies during treatment of low-grade cutaneous T-cell lymphomas with interferon alpha-2a combined with acitretin or PUVA.
    Rajan GP; Seifert B; Prümmer O; Joller-Jemelka HI; Burg G; Dummer R
    Arch Dermatol Res; 1996 Aug; 288(9):543-8. PubMed ID: 8874750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low incidence of neutralizing antibody formation to interferon-alpha 2b in human recipients.
    Dianzani F; Antonelli G; Amicucci P; Cefaro A; Pintus C
    J Interferon Res; 1989 Sep; 9 Suppl 1():S33-6. PubMed ID: 2681442
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autoantibodies to crude human leucocyte interferon (IFN), native human IFN, recombinant human IFN-alpha 2b and human IFN-gamma in healthy blood donors.
    Ross C; Hansen MB; Schyberg T; Berg K
    Clin Exp Immunol; 1990 Oct; 82(1):57-62. PubMed ID: 2119920
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group.
    Bajetta E; Zilembo N; Di Bartolomeo M; Di Leo A; Pilotti S; Bochicchio AM; Castellani R; Buzzoni R; Celio L; Dogliotti L
    Cancer; 1993 Nov; 72(10):3099-105. PubMed ID: 7693327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.